113 results about "B-Cell Epitopes" patented technology

The invention discloses a citrullinated SAA polypeptide and application thereof in preparation of a rheumatoid arthritis diagnosis product, the amino acid sequence of the citrullinated SAA polypeptide is DKYFHA-Cit-GNYDAAK-Cit-GPGGA, through the polypeptide, the citrullinated autoantigen B cell epitope of SAA and a corresponding autoantibody, namely an anti-citrullinated SAA polypeptide antibody (anti-CAP), are identified. The expression level of anti-CAP in RA patients is obviously higher than that of other disease control groups and healthy groups, and the anti-CAP has better positive rate in early RA, ESR / CRP normal RA and anti-CCP antibody / RF negative RA, and provides a new strategy for diagnosis of RA.

The invention discloses a camel source single-domain antibody GH12 for recognizing a conformation B cell epitope in clostridium difficile glutamate dehydrogenase and application of the camel source single-domain antibody GH12. The nucleotide sequence of the camel source single-domain antibody GH12 is shown as SEQ ID NO: 1, and the amino acid sequence of the camel source single-domain antibody GH12 is shown as SEQ ID NO: 2. The camel source single-domain antibody GH12 disclosed by the invention has the advantages of strong specificity, high sensitivity, good accuracy and the like, and it is proved that the camel source single-domain antibody GH12 can be used for detecting recombinant expressed CD-GDH and endogenous CD-GDH by enzyme-linked immunosorbent assay (ELISA), protein dot blot hybridization (DB) and other methods.

The embodiment of the invention is to conformationally constrain neutralizing B cell epitopes of CoV-2, CoV-n B cell epitopes of the open reading frame proteins, including the membrane S protein, constrained by protein scaffolds, including camelid VHH nanobody in order to elicit neutralizing and blocking antibodies against viral infection. B cell epitopes are molecularly evolved by ribosome display to preempt emerging viral B cell epitopes. Moreover, CTL epitopes are designed from the open reading frame protein for eliciting cell mediated viral protection. Furthermore, mRNA vaccines are prepared for eliciting protective immunity and prevent cytokine storms.

The invention discloses a chicken infectious anemia virus subunit vaccine, and belongs to the technical field of animal disease vaccines. The invention provides a chicken infectious anemia virus subunit vaccine. Active ingredients of the chicken infectious anemia virus subunit vaccine are recombinant fusion protein of chicken infectious anemia virus VP1 protein B cell epitope and salmonella typhimurium flagellin. The B cell epitope of the chicken infectious anemia virus VP1 protein is obtained by connecting B cell antigen epitopes contained in the chicken infectious anemia virus VP1 protein through a connecting peptide. The salmonella typhimurium flagellin is obtained by deleting a hypervariable region of the salmonella typhimurium flagellin FliC. The fusion expression protein provided by the invention can induce generation of a specific IgG antibody after one-day-old SPF chicken, and after immunization for 28 days, immunized chicken flocks can resist challenge of chicken infectious anemia virus virulent strains, and 70% of challenge chicken flocks are protected without disease attack. The invention has great potential for clinical prevention and control of chicken infectious anemia virus infection.

The invention discloses a preparation method and application of porcine pseudorabies virus multi-epitope polypeptide, and belongs to the technical field of veterinary biological products. The multi-epitope polypeptide comprises a cytotoxic T cell epitope, a helper T cell epitope and a linear B cell epitope; the cell epitopes are screened from key immunogenic proteins of the pseudorabies virus by using an immunoinformatics method. The porcine pseudorabies virus multi-epitope polypeptide designed by the invention is high in safety, has better antigenicity and physicochemical properties, can be efficiently expressed, and can be recognized by a pseudorabies virus specific antibody. By applying the porcine pseudorabies virus multi-epitope polypeptide, high-level specific antibodies and cellular immune response can be continuously induced to generate, strong protective efficacy is generated, and mice can be protected from death when infected with a lethal dose of porcine pseudorabies virus. Therefore, the multi-epitope polypeptide disclosed by the invention can be used as an alternative antigen of a porcine pseudorabies virus vaccine, the use of active virus is avoided, and a tool is provided for eradication of porcine pseudorabies virus.

The invention is applicable to the technical field of biology, and provides an L7 / L12-PADRE sequence-multi-linked B cell epitope recombinant protein and a kit for detecting an anti-Brucella antibody. The recombinant protein is a multi-epitope tandem recombinant protein composed of Brucella ribosome L7 / L12 protein, a PADRE polypeptide sequence and multiple B cell epitopes, the amino acid sequence of the recombinant protein is as shown in SEQ ID No.1, and the recombinant protein is good in antigenicity. The anti-brucella antibody indirect ELISA (iELISA) detection method and kit established by taking the recombinant protein as the coating antigen have the characteristics of high sensitivity, strong specificity and good repeatability, are suitable for detecting the condition of generating the anti-brucella antibody by an organism, can clarify the immune background of brucella infection or brucellosis vaccine, and can be used for detecting the brucella infection or brucellosis vaccine. Basic data is provided for prevention and control of the Brucella disease of humans and animals, and meanwhile, the kit is conveniently applied to large-scale sample detection and epidemiological monitoring.

The invention discloses a porcine delta coronavirus spike protein monoclonal antibody, an antigen epitope peptide and application, and belongs to the technical field of biology. The antibody comprises a light chain variable region and a heavy chain variable region, the amino acid sequence of the light chain variable region is as shown in SEQ ID No.1, and the amino acid sequence of the heavy chain variable region is as shown in SEQ ID No.3. According to the invention, a highly conservative linear B cell epitope (the amino acid sequence is DFGEARLD) of a PDCoV spike protein receptor binding domain (S-RBD) and a neutralizing monoclonal antibody capable of being specifically bound to the epitope are identified for the first time. The epitope peptide and the monoclonal antibody provided by the invention can be used for immunological detection and serological investigation of the PDCoV.

The invention provides a streptococcus suis vaccine recombinant fusion protein and a preparation method and application thereof, the recombinant fusion protein is a recombinant protein formed by series fusion of B cell epitopes of Sao, SLY and PepO proteins of streptococcus suis, and the amino acid sequence of the fusion protein is as shown in SEQ ID NO.1. After four-week-old weaned piglets are immunized by the fusion expression protein for 28 days, 80% and 60% of challenge protection rates can be provided for challenge of streptococcus suis type 2 and type 9 virulent strains respectively. The invention has great potential for clinical prevention and control of streptococcus suis infection.

The invention discloses an ILTV gD protein antigen epitope expression cassette, a recombinant virus and application, and relates to the field of gene and protein engineering. The ILTV gD protein antigen epitope expression cassette provided by the invention comprises T and B cell epitopes of gD protein derived from an infectious laryngotracheitis virus WG strain. The recombinant virus rH120-gD-T / B is obtained by replacing a 5ab gene of an infectious bronchitis virus H120 strain with a gene for coding an ILTV gD protein antigen epitope expression cassette. The recombinant virus has good genetic stability, can be used for developing a safe and effective IB-ILT bivalent live vector vaccine, and solves the problem of poor stability of the current recombinant IBV.

The invention provides an avian adenovirus D11 type tandem multi-epitope vaccine, and belongs to the technical field of veterinary vaccines. According to the invention, an amino acid sequence of fiber protein of the fowl adenovirus D11 type is analyzed, 10 potential B cell epitopes are screened out, 10 antigen epitopes are artificially synthesized to prepare the vaccine, and six antigen epitopes with high neutralizing antibody titer are screened out by immunizing chicken. Flexible peptides are designed among the screened six antigen epitopes for connection, and a series multi-epitope antigen is designed. The oil emulsion vaccine is prepared by expressing tandem multi-epitope antigen protein through recombinant escherichia coli, purifying through a nickel column, and emulsifying with a mineral oil adjuvant. All test chickens immunized by the series multi-epitope vaccine in an over-dose manner have no abnormities in spirit, ingestion and water drinking, injection parts have no red and swollen reactions, and the vaccine is good in safety. The series multi-epitope vaccine has a good immune effect, can enable the immunized chicken to generate a neutralizing antibody to achieve challenge protection, and can block the detoxification of the challenge chicken.

The invention belongs to the technical field of biological medicines, and particularly relates to a PPV-PCV2 nanoparticle vaccine design and a preparation method. According to the invention, PPV1VP2 protein is used as a skeleton, a SpyTag peptide fragment is inserted into a loop 2 region of the VP2 protein, and the fusion protein is expressed by using an insect cell baculovirus system and is marked as PPV-ST; a plurality of B cell epitopes of Cap protein of PCV2 and a plurality of T cell antigen epitopes of Rep protein of PCV2 are connected in series, a SpyCatcher peptide fragment is fused at an N end, and expression is performed by using a prokaryotic expression system and is marked as SC-PCV2. Finally, the PPV-ST protein and the SC-PCV2 protein are subjected to covalent binding assembly, the nanoparticle vaccine is prepared, and the obtained PPV-PCV2 vaccine has good immunogenicity.

The invention discloses a multi-epitope peptide of novel coronavirus, a vaccine as well as a preparation method and application of the multi-epitope peptide, and belongs to the technical field of preparation of polypeptide vaccines. The multi-epitope peptide of the novel coronavirus not only contains T cell epitopes, but also contains B cell epitopes, and can induce humoral immunity and cellular immunity responses of an organism at the same time; the vaccine comprises epitopes from four antigenic proteins of novel coronavirus, and can induce comprehensive immune response. According to the multi-epitope peptide vaccine based on the novel coronavirus, the nano-carrier KFE8 serves as a delivery carrier, different antigen epitopes of the same pathogen or antigen epitopes of different pathogens can be presented in a mixed mode, safety is good, large-scale rapid preparation is achieved in an emergency state, and the vaccine is suitable for large-scale popularization and application. The coronavirus vaccine is a novel coronavirus universal vaccine which can cover various pathogen subtypes and induce broad-spectrum and long-term immune effects.

The invention belongs to the field of biological immunity, and discloses a linear B cell epitope of African swine fever virus NP419L protein and application. The epitope sequence shows good immunoreactivity through ASFV positive pig serum recognition verification. The African swine fever positive serum can be identified by using the B cell epitope identified by the invention to carry out ELISA (Enzyme-Linked Immunosorbent Assay) experiment, and the sensitivity of the African swine fever positive serum is superior to that of NP419L protein full length and other truncated fragments. The epitope identified by the invention has high conservative property in reference ASFV strains in a plurality of popular regions in China, and has wide universality and adaptability. The kit can be widely applied to etiological diagnosis, serological diagnosis, immunological detection and disease prevention and treatment of African swine fever viruses, and can be applied to preparation of African swine fever vaccines, pathogenesis research and the like.

In order to seek an echinococcosis antigen which has good immunogenicity and can activate an organism to generate an effective immune response against echinococcosis granulosa infection, the invention provides an echinococcosis multi-epitope antigen and application thereof in preparation of a vaccine for preventing echinococcosis. The multi-epitope antigen is formed by sequentially connecting CTLA-4-lgV, a T cell epitope of EgA31, a T cell epitope of EgG1Y162, a B cell epitope of EgA31 and a B cell epitope of EgG1Y162 in series, the multi-epitope antigen can be specifically combined with serum of a cystic echinococcosis patient, a mouse immunized by a vaccine can generate specific B cell response and generate specific cellular immunity and an antibody, and the multi-epitope antigen has good immunogenicity.

The invention is applicable to the technical field of genetic engineering and biological medicine, and provides construction of a fusion recombinant protein ABT for preventing brucellosis and application of the fusion recombinant protein ABT in preparation of protective vaccines. The fusion recombinant protein ABT is composed of an immunological enhancement antigen and a multi-epitope tandem antigen, wherein the immunological enhancement antigen (named as A) comprises a Brucella ribosome L7 / L12 protein and a PADRE sequence; the multi-epitope tandem antigen is formed by connecting a dominant B cell epitope part (named as B), a dominant Tc cell epitope part and a dominant Th cell epitope part (named as T) in series, wherein the dominant B cell epitope part (named as B) is derived from Brucella SurA, OMP31, BP26 and Trigger factor proteins. The ABT Brucella multi-epitope subunit vaccine prepared by mixing the fusion recombinant protein ABT and an immunologic adjuvant has the characteristics of good purity, high safety and strong immunogenicity, can stimulate an organism to generate a protective antibody, and has long antibody maintenance time.

The invention relates to the technical field of biological medicine, and discloses a nanoparticle vaccine based on an HER2 target spot and application of the nanoparticle vaccine, and the nanoparticle vaccine based on the HER2 target spot comprises an HER-2 gene related antigen sequence HER2 and hepatitis B core virus-like particle nanoparticles HBc VLPs; the amino acid sequences of the gene are respectively shown as SEQ ID No. 1 and SEQ ID No. 2. According to the invention, hepatitis B core virus-like particles are modified by using B cell epitopes of HER2 targets, and the nanoparticle tumor vaccine suitable for intramuscular injection is prepared. The vaccine aims at reducing clinical safety risks and reducing immune tolerance and toxic and side effects caused by long-term use of monoclonal antibody drugs. Through an active immunization mode, an organism can continuously generate an anti-HER2 specific antibody, and clinical guidance is provided for research and development of therapeutic general tumor vaccines.

The present disclosure relates to a method for designing a personalized cancer vaccine, using a B cell-reactive neoantigen, the method comprising the steps of: receiving a peptide sequence extracted from cancer tissue and allelic sequence data of B cell receptors; calculating the preferential binding strength between amino acids in the peptide sequence and allelic sequences of B cell receptors; and calculating B cell epitope prediction scores by inputting the preferential binding strength between amino acids to a trained neural network model.

The invention discloses a conservative B cell epitope peptide of goose parvovirus VP3 protein, a nucleic acid molecule, a recombinant vector and application thereof. Conservative B cell epitope EW12 is inserted into F18 Escherichia coli Fod fimbriae, inert carrier bacteria S9H are introduced, recombinant bacteria capable of functionally exhibiting and expressing the EW12 conservative B cell epitope on the surface of the bacteria are obtained, the recombinant bacteria can specifically generate specific binding reaction with gosling plague egg yolk antibody and gosling plague vaccine immune serum, and the gosling plague egg yolk antibody and the gosling plague vaccine immune serum can be specifically combined with the gosling plague egg yolk antibody and the gosling plague vaccine immune serum. The method has the advantages that macroscopic agglutination particles are generated, cross agglutination reaction with other pathogen positive serum and healthy goose serum is avoided, the method is good in sensitivity, and the specific antibody can be detected in the 5th day after immunization at the earliest. A plate agglutination test directly mediated by the goose parvovirus VP3 protein conservative B cell epitope peptide EW12 has the advantages of specificity, sensitivity, convenience in operation and suitability for on-site large-scale rapid detection, and is expected to provide a new technical means for diagnosis, prevention and control and purification of GPV infection.

The invention provides a vaccine composition comprising an influenza virus peptide comprising a CD8+ T cell epitope and an influenza virus peptide comprising a B cell epitope, wherein each peptide is attached to a nanoparticle.

The application discloses a duck Riemerella anatipestifer (RA) surface adhesion factor 3-glyceraldehyde-3-phosphate dehydrogenase protein (GAPDH) conservative B cell epitope peptide, a nucleic acid molecule, a recombinant carrier and application thereof. The application inserts the conservative B cell epitope TG12 into chicken white dysentery Salmonella Peg fimbria, introduces the inert carrier bacteria, and obtains the recombinant bacteria which can functionally express and present the RaGAPDH protein surface conservative B cell epitope peptide. The expression and presentation of the conservative B cell epitope can specifically recognize and combine duck and goose RA infection serum, and the naked-eye visible agglutination reaction particles are observed, and there is no cross agglutination reaction with other pathogen infection positive serum. The agglutination detection method has the advantages of specificity and convenience, and is expected to provide a new idea and method for detection and prevention and control of RA infection.

Provided herein are HER-3, HER-1 and IGF-1R B cell epitopes, peptide mimics, chimeric peptides and multivalent peptides. In some embodiments, the chimeric peptides include one or more HER-3, HER-1 and / or IGF-1R B cell epitopes, a linker, and a T helper cell (Th cell) epitope. Pharmaceutical compositions are also provided that contain one or more HER-3, HER-1 and / or IGF-1R chimeric peptides, and optionally, one or more HER-2 chimeric peptides and / or VEGF peptides. Also included herein are methods of treating a cancer using the HER-3, HER-1 and IGF-1R B cell epitopes, chimeric peptides and multivalent peptides.

The present invention discloses a subunit vaccine against chicken infectious anemia virus, belonging to the technical field of animal disease vaccines. The present invention provides a subunit vaccine against chicken infectious anemia virus, and the active ingredient is a recombinant fusion protein of the B cell epitope of chicken infectious anemia virus VP1 protein and Salmonella typhimurium flagellin. The B cell epitope of chicken infectious anemia virus VP1 protein is obtained by connecting the B cell antigen epitopes contained in chicken infectious anemia virus VP1 protein through a linker peptide. The Salmonella typhimurium flagellin is obtained by deleting the hypervariable region of Salmonella typhimurium flagellin FliC. After the fusion expression protein of the present invention is administered to 1-day-old SPF chickens, it can induce the production of specific IgG antibodies, and after 28 days of immunization, the immunized chicken flock can resist the challenge of the virulent strain of chicken infectious anemia virus, and 70% of the challenged chicken flock is protected from disease. The present invention has great potential for clinical prevention and control of chicken infectious anemia virus infection.

The invention relates to a self-adjuvant based on a virus source glycopeptide and an application of the self-adjuvant in preparation of a vaccine, the self-adjuvant is a glycopeptide fragment based on a varicella-zoster virus (VZV) source, and the self-adjuvant is a B cell epitope structural domain V50 glycopeptide (from 50 valine to 135 isoleucine, V50-I135) in glycoprotein E. The invention further relates to a preparation method of the self-adjuvant based on the virus source glycopeptide and application of the self-adjuvant based on the virus source glycopeptide in preparation of the vaccine. The V50 glycopeptide and the novel coronavirus RBD are subjected to fusion expression and then are coupled to the surfaces of the nanoparticles based on ferritin to form the self-adjuvant vaccine, so that the levels of RBD specific antibodies and pseudovirus neutralizing antibodies induced by the RBD nanoparticle vaccine can be remarkably enhanced, and the V50 glycopeptide has a synergistic effect in B cell response and T cell response of systemic systemic immunity and mucosal immunity at the same time. The immune protection effect of the novel coronavirus RBD nanoparticle vaccine is obviously improved.

The invention relates to a preparation method of a babesiella bovis vaccine, belongs to the technical field of vaccines, and particularly relates to a combined vaccine based on silver nanoparticles (AgNPs) and theileria bovis antigen, the vaccine comprises 10-50nm AgNPs, the surface of the AgNPs is modified with carboxyl, amino or PEG, and the AgNPs are used for covalently coupling RAP-1 protein or immunogenic fragments thereof and MSA-2 protein or B cell epitope peptide thereof, the RAP-1 protein comprises an amino acid sequence (nucleotide sequence is as shown in SEQ ID NO: 1), the MSA-2 protein comprises an amino acid sequence (nucleotide sequence is as shown in SEQ ID NO: 2), and the preparation method comprises the following steps: carrier construction, recombinant expression, protein purification and AgNPs coupling to form a silver nanoparticle antigen compound, and the silver nanoparticle antigen compound is coated with chitosan to prolong the in-vivo half-life period.

The invention belongs to the technical field of genetic engineering, and particularly relates to a bovine group A rotavirus multi-epitope fusion protein and application thereof. The invention provides a bovine group A rotavirus multi-epitope peptide based on a ferritin nano-carrier, a fusion protein and application of the bovine group A rotavirus multi-epitope peptide and the fusion protein. The multi-epitope peptide disclosed by the invention is a multi-epitope fusion antigen which is formed by splicing cytotoxic T lymphocyte epitopes, helper T cell epitopes and B cell epitopes with high conservative property and strong immunogenicity and is formed by screening and obtaining the cytotoxic T lymphocyte epitopes, helper T cell epitopes and B cell epitopes with high conservative property and strong immunogenicity on the basis of VP4 and VP7 protein sequences of bovine group A rotaviruses by utilizing an immunoinformatics technology. Immunological evaluation shows that the monoclonal antibody has good antigen specificity and neutralizing activity. Animal experiment results show that the epitope peptide and the fusion protein can induce an organism to generate high-level neutralizing antibodies aiming at BRVA G6, G8, G10 and other multi-genotype strains, and the broad spectrum and durability of immune protection are remarkably improved.

The invention relates to the technical field of microorganisms, and discloses construction and application of an enterotoxigenic escherichia coli K88 cilia display system. A K99 FanC sequence is subjected to B cell epitope prediction analysis, the FanC gene is divided into different antigen regions, the antigen regions are subjected to fusion expression with FaeG protein, the separated and purified fusion protein is used as an antigen to immunize mice, and the optimal fusion protein FaeG-EP3 is screened out, and the protein is shown as SEQ ID NO.9. The invention further discloses a preparation method of the FanC protein. While the Escherichia coli K99 ciliin epitope is fully exposed, the ciliin of the K88 native conformation is expressed, the original protein activity is ensured, and the protein expression is stable and efficient. And the method has important significance for solving the problem of complex types of porcine enterotoxigenic escherichia coli pili adhesin.

The present invention belongs to the technical field of vaccines and relates to an encephalomyocarditis multi-epitope recombinant protein, and the encephalomyocarditis multi-epitope recombinant protein comprises 8 B-cell epitopes and 1 signal peptide. The present invention also provides the application of the recombinant protein in the preparation of an encephalomyocarditis vaccine. With the goal of developing a safe and effective vaccine, the B-cell epitopes of VP1, VP2, and VP3 of the EMCV structural protein are screened, and a recombinant epitope protein with good hydrophilicity, strong antigenicity, and high surface accessibility is constructed. By immunizing BALB / c mice, it is found that it can induce the production of neutralizing antibodies and a Th1-dominated cellular immune response, and can protect the mice from EMCV attack. The results show that the MIgH-EMCV-II<supgt;2D2< / supgt; protein may be a potential candidate for developing a safe and effective multi-epitope vaccine to control EMCV infection.

The present invention discloses citrullinated SAA polypeptides and their application in the preparation of diagnostic products for rheumatoid arthritis. The amino acid sequence of the citrullinated SAA polypeptide is: DKYFHA-Cit-GNYDAAK-Cit-GPGGA. Through this polypeptide, the present invention has identified the citrullinated autoantigen B cell epitope of SAA and the corresponding autoantibody, namely anti-citrullinated SAA polypeptide antibody (anti-CAP). The expression level of anti-CAP in RA patients is significantly higher than that in other disease control groups and healthy groups, and it has a good positive rate in early RA, ESR / CRP normal RA, and anti-CCP antibody / RF negative RA, providing a new strategy for the diagnosis of RA.

The application discloses a porcine delta coronavirus S1-CTD protein linear B cell epitope peptide and application thereof, and belongs to the technical field of biological medicines. 585 EYLQVQAEQVIVDCP 599 The linear B cell epitope peptide can be recognized and combined by a monoclonal antibody of the porcine delta coronavirus S1-CTD protein, and provides technical support for research and development of porcine delta coronavirus related vaccines, medicines and diagnostic reagents.

The application discloses a bovine parainfluenza virus 3A and 3C type polyepitope antigen peptide, a complex thereof and application. The polyepitope antigen peptides BPMEV-3A and BPMEV-3C have amino acid sequences as shown in SEQ ID NO:1 and SEQ ID NO:3 respectively, and are connected by screening CTL epitopes, HTL epitopes and B cell epitopes from HN and F proteins of BPIV-3A and BPIV-3C strains. Animal immunization tests show that the antigen peptide and the complex thereof can effectively stimulate the body to produce specific IgG antibodies and neutralizing antibodies, induce Th1 type cellular immune response, and effectively eliminate viruses and reduce lung tissue lesions, and show good immunogenicity and protection effect. The application provides an efficient and safe vaccine candidate for prevention and control of BPIV-3, and has a good application prospect.